In-vivo effect of 5HLS and talazoparib combination on tumor growth. (IMAGE)
Caption
(A) Tumor volume and body weight of mice treated by vehicle (Veh), 5HLS, talazoparib (Tal), or combination (Comb) of 5HLS and talazoparib.
(B, C) Gross anatomy (B) and wet weight (C) of dissected xenograft tumors at the end of the study. (
D) Synergy analysis. Tumor growth inhibition (TGI) was derived using the wet weight of tumors. The expected combination inhibition (C(E)) was calculated from that of 5HLS and talazoparib alone using the Bliss independence model (see Materials and Methods). C(O) represents the observed combination inhibition.
(E) Immunohistochemical analyses of FASN, PARP, and γH2AX. Scale bar, 50 μm.
(F) Western blotting analyses of FASN, BRCA1, PARP1, cleaved PARP1 (cPARP1), γH2AX, and actin loading control in xenograft tumors from mice treated with vehicle, 5HLS, talazoparib, and the combination of 5HLS and talazoparib. Each lane represents mixed samples of five tumors in equal proportion within the treatment group. n = 5; ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001.
Credit
Sophia Josephraj, Chao J. Wang, Qingbin Cui, Zizheng Dong, Jing-Yuan Liu, Jian-Ting Zhang
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND